Atrial natriuretic factor improves renal function and lowers systolic blood pressure in renal allograft recipients treated with cyclosporin A

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide) in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.

Who Took Part

PubMed indexes the participants as middle-aged adults.

How the Study Was Run

The design is described as randomized, single-blind, placebo-controlled and crossover.

Because people in this ANP (Atrial Natriuretic Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the participants, was kept unaware of whether ANP (Atrial Natriuretic Peptide) was given.

The comparison arm used a placebo, so changes seen with ANP (Atrial Natriuretic Peptide) could be set against what happens without it.

In the crossover set-up each of the participants took both ANP (Atrial Natriuretic Peptide) and the comparison in turn, acting as their own control.

A single-blind randomized crossover design comparing the renal and haemodynamic effects of D-glucose (placebo) with ANF.

What Was Measured

The subject headings attached to it are Atrial Natriuretic Factor, Blood Pressure, Cyclosporine, Kidney, Kidney Function Tests, Kidney Transplantation and Renal Circulation.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in people with low blood pressure and orthostatic hypotension.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1992 (Journal of hypertension), a journal based in Netherlands.

More context: the ANP (Atrial Natriuretic Peptide) compound page, Low blood pressure and orthostatic hypotension research.